Second-line tarlatamab improves OS in SCLC Summary Second-line treatment with tarlatamab, a DLL3-targeting bispecific T-cell engager, significantly improved overall survival (OS) in patients with relapsed or refractory small cell lung cancer (SCLC) compared to Read More